Abstract 5942
Background
Fatigue represents a complex and frequent symptom in cancer patients and influences their quality of life. Although nurses consider the initial evaluation of the patient to be fundamental, this problem is underestimated in clinical practice and often leads to under-treatment. In addition, the patients and their families still often do not report the symptom because they fear that it will lead to a reduction or suspension of treatment or they think that the symptom is inevitable.
Methods
Mixed methods study. Data were collected using Brief Fatigue Inventory, patients’ interviews, focus groups with nurses and analysis of patients’ records. The setting is represented by two impatient departments of Oncology Institute of Southern Switzerland. Quantitative data were analysed with SPSS 22.0. For the interviews and focus groups, the analysis processes were conducted according to conventional content analysis using Nvivo 10 software.
Results
71 questionnaires were analysed, 39 males and 32 females. The mean age was 65,7±14 years. Fatigue was reported 5 times (7%) in nursing documents and 17 times problems fatigue was reported by nurses 5 times (7%) in patients’ records, while in 17 cases (23.9%) related problems were reported. 12 patients were interviewed. Five themes were identified: feeling powerless and aggressive, my strategies or what helps me, feeling reassured by the presence of family members, feeling reassured by nurses’ gesture, to be informed. Three themes were identified from nurses focus group: objectivity and subjectivity in the assessment of asthenia, nursing contribution in the multidisciplinary management of asthenia and difficulty in evaluating outcomes.
Conclusions
A not systematic approach to the management of fatigue emerges. Patients are satisfied with the care received but would like more information and specific interventions. Quantitative and qualitative results seem converge. Fatigue is still an underestimated problem in clinical practice. Specific training interventions for health professionals are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific Research Advisory Board (ABREOC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract